<?xml version="1.0" encoding="utf-8" standalone="yes" ?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>Wendy Ingram | Kristian Brock</title>
    <link>/authors/wendy-ingram/</link>
      <atom:link href="/authors/wendy-ingram/index.xml" rel="self" type="application/rss+xml" />
    <description>Wendy Ingram</description>
    <generator>Source Themes Academic (https://sourcethemes.com/academic/)</generator><language>en-us</language><lastBuildDate>Thu, 17 Jan 2019 00:00:00 +0000</lastBuildDate>
    <image>
      <url>/img/icon-192.png</url>
      <title>Wendy Ingram</title>
      <link>/authors/wendy-ingram/</link>
    </image>
    
    <item>
      <title>Combination Lenalidomide and Azacitidine - A Novel Salvage Therapy in Patients Who Relapse After Allogeneic Stem-Cell Transplantation for Acute Myeloid Leukemia</title>
      <link>/publication/viola-results/</link>
      <pubDate>Thu, 17 Jan 2019 00:00:00 +0000</pubDate>
      <guid>/publication/viola-results/</guid>
      <description>&lt;p&gt;This publication is important to me because Viola was the first dose-finding trial that I worked on.
It uses a CRM model to identify a dose of lenalidomide that is tolerable when given with azacitidine to AML and MDS patients.
This was also one of my first published sets of trial results.&lt;/p&gt;
</description>
    </item>
    
  </channel>
</rss>
